As the first psychedelic-assisted therapies head towards potential regulatory approvals, we’re becoming increasingly focused on the challenges that drug developers, providers and patients may face in rolling out and accessing these treatments at scale. One such challenge will be the availability of an appropriately trained and adequately incentivised pool of providers (which might be called…
